[Acquired factor Ⅴ inhibitor induced by surgical trauma complicated with fatal hemorrhage: a case report and literature review].

Q3 Medicine
Y H Zhang, X Pan, X X Chu, W Xu
{"title":"[Acquired factor Ⅴ inhibitor induced by surgical trauma complicated with fatal hemorrhage: a case report and literature review].","authors":"Y H Zhang, X Pan, X X Chu, W Xu","doi":"10.3760/cma.j.cn121090-20241128-00491","DOIUrl":null,"url":null,"abstract":"<p><p><b>Objective:</b> To explore the diagnosis, treatment, and prognosis of patients with acquired factor Ⅴ inhibitors. <b>Methods:</b> We analyzed a case of acquired factor Ⅴ inhibitor treated in the department of critical care medicine at Shanghai East Hospital in 2022. A literature review was conducted using the search terms [ (\"Factor V\" OR \"Factor V Inhibitors\") AND (\"Autoantibodies\" OR \"Immune System Diseases\") ] AND [acquired (Title/Abstract) OR autoimmune (Title/Abstract) OR inhibitor (Title/Abstract) ] in the PubMed database. Chinese databases (Wanfang, VIP, and CNKI) were searched using (acquired factor V inhibitor OR acquired coagulation factor V inhibitor OR coagulation factor V antibody OR coagulation factor V autoantibody) AND (deficiency OR inhibition OR dysfunction) . <b>Results:</b> A 56-year-old male was admitted to the department of critical care medicine due to coagulopathy following surgery. Laboratory tests showed normal blood routine but revealed prolonged PT of 76.7 s, APTT of 83.1 s, and an INR of 7.14. Coagulation factor assays indicated factor V activity at 8.4%, which continued to decline. Immediate and 2-hour delayed mixing studies failed to correct the coagulation abnormalities. The factor V inhibitor titer was measured at 8 BU/ml. It was considered that surgical trauma induced the production of an acquired factor V inhibitor, leading to fatal bleeding. After treatment with corticosteroids, cyclophosphamide, and plasma exchange, the coagulation abnormalities were corrected. The literature search identified 16 cases reported in China and approximately 200 cases reported globally. <b>Conclusion:</b> Patients with acquired factor V inhibitors exhibit diverse clinical manifestations. Current treatment options include combined therapies such as supportive care, corticosteroids, immunosuppressants, and plasma exchange. The prognosis of patients depends on the inducing factors and the timeliness of diagnosis and treatment.</p>","PeriodicalId":24016,"journal":{"name":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","volume":"45 S1","pages":"36-39"},"PeriodicalIF":0.0000,"publicationDate":"2024-12-30","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Zhonghua xue ye xue za zhi = Zhonghua xueyexue zazhi","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3760/cma.j.cn121090-20241128-00491","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"Medicine","Score":null,"Total":0}
引用次数: 0

Abstract

Objective: To explore the diagnosis, treatment, and prognosis of patients with acquired factor Ⅴ inhibitors. Methods: We analyzed a case of acquired factor Ⅴ inhibitor treated in the department of critical care medicine at Shanghai East Hospital in 2022. A literature review was conducted using the search terms [ ("Factor V" OR "Factor V Inhibitors") AND ("Autoantibodies" OR "Immune System Diseases") ] AND [acquired (Title/Abstract) OR autoimmune (Title/Abstract) OR inhibitor (Title/Abstract) ] in the PubMed database. Chinese databases (Wanfang, VIP, and CNKI) were searched using (acquired factor V inhibitor OR acquired coagulation factor V inhibitor OR coagulation factor V antibody OR coagulation factor V autoantibody) AND (deficiency OR inhibition OR dysfunction) . Results: A 56-year-old male was admitted to the department of critical care medicine due to coagulopathy following surgery. Laboratory tests showed normal blood routine but revealed prolonged PT of 76.7 s, APTT of 83.1 s, and an INR of 7.14. Coagulation factor assays indicated factor V activity at 8.4%, which continued to decline. Immediate and 2-hour delayed mixing studies failed to correct the coagulation abnormalities. The factor V inhibitor titer was measured at 8 BU/ml. It was considered that surgical trauma induced the production of an acquired factor V inhibitor, leading to fatal bleeding. After treatment with corticosteroids, cyclophosphamide, and plasma exchange, the coagulation abnormalities were corrected. The literature search identified 16 cases reported in China and approximately 200 cases reported globally. Conclusion: Patients with acquired factor V inhibitors exhibit diverse clinical manifestations. Current treatment options include combined therapies such as supportive care, corticosteroids, immunosuppressants, and plasma exchange. The prognosis of patients depends on the inducing factors and the timeliness of diagnosis and treatment.

[手术创伤并发致死性出血的获得性因子Ⅴ抑制剂1例并文献复习]。
目的:探讨获得性因子Ⅴ抑制剂的诊断、治疗及预后。方法:对上海东方医院2022年收治的1例获得性因子Ⅴ抑制剂进行分析。使用PubMed数据库中的搜索词[(“因子V”或“因子V抑制剂”)和(“自身抗体”或“免疫系统疾病”)]和[获得性(标题/摘要)或自身免疫性(标题/摘要)或抑制剂(标题/摘要)]进行文献综述。使用(获得性因子V抑制剂或获得性凝血因子V抑制剂或凝血因子V抗体或凝血因子V自身抗体)和(缺乏或抑制或功能障碍)检索中国数据库(万方、维普和中国知网)。结果:56岁男性,术后因凝血功能障碍入住重症医学科。实验室检查显示血常规正常,但PT延长76.7 s, APTT延长83.1 s, INR为7.14。凝血因子测定表明,因子V活性为8.4%,并持续下降。即时和2小时延迟混合研究未能纠正凝血异常。测定因子V抑制剂滴度为8 BU/ml。人们认为,手术创伤诱导了获得性因子V抑制剂的产生,导致了致命的出血。经皮质类固醇、环磷酰胺和血浆置换治疗后,凝血异常得到纠正。文献检索确定了中国报告的16例病例和全球报告的约200例病例。结论:获得性因子V抑制剂患者临床表现多样。目前的治疗方案包括联合治疗,如支持治疗、皮质类固醇、免疫抑制剂和血浆交换。患者的预后取决于诱发因素和诊治的及时性。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
0.80
自引率
0.00%
发文量
100
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信